Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002222 · ClinicalTrials.gov registry record · NA

A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS

A NA study of HIV Infections and Cytomegalovirus Retinitis, sponsored by Hoffmann-La Roche.

Completed
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT00002222 is a NA study of HIV Infections and Cytomegalovirus Retinitis that has completed, run by Hoffmann-La Roche. The registered enrollment target is 200 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002222, a NA study of HIV Infections and Cytomegalovirus Retinitis, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to see if valganciclovir is a safe treatment for CMV retinitis in patients who have been treated for this condition in the past. This study also examines the effectiveness of valganciclovir in preventing the recurrence of CMV retinitis.

Conditions Studied

HIV Infections Cytomegalovirus Retinitis

Interventions

  • DRUG Valganciclovir

Study Locations (1)

New York

  • Cornell AIDS Clinical Trials Unit - New York

Trial Details

FieldValue
Enrollment Target 200 participants
Phase NA

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00002222

The ClinicalTrials.gov registry entry for NCT00002222 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Valganciclovir is the first listed.

NCT00002222 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00002222 about?

NCT00002222 is a clinical study titled "A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS". The purpose of this study is to see if valganciclovir is a safe treatment for CMV retinitis in patients who have been treated for this condition in the past. This study also examines the effectiveness of valganciclovir in preventing the recurrence of CMV retinitis.

What is the current status of trial NCT00002222?

This trial is currently completed. It is a NA study. The enrollment target is 200 participants.

What conditions does trial NCT00002222 study?

This clinical trial studies the following conditions: HIV Infections, Cytomegalovirus Retinitis.

What interventions are being tested in trial NCT00002222?

The interventions under investigation include: Valganciclovir (DRUG).

Who is sponsoring clinical trial NCT00002222?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002222 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Cytomegalovirus Retinitis

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.